Stockscreener 앱 받기
1.50
4.17%
0.06
시장 영업 전:
1.47
-0.03
-2.00%
Compugen Ltd 주식(CGEN)의 최신 뉴스
Leerink Partnrs Predicts Increased Earnings for Compugen - Defense World
Can Compugen Ltd. hit a new high this monthShort-Term Price Breakout Signal Analysis - Newser
Real time pattern detection on Compugen Ltd. stockFree Access to Real-Time Trade Insights - Newser
Compugen Ltd. stock prediction for this weekMarket Correction Proof Stock Screening Analysis - Newser
Compugen signals leadership transition and advances COM701 ovarian cancer trial with interim data targeted for 2026 - MSN
Need To Know: Analysts Just Made A Substantial Cut To Their Compugen Ltd. (NASDAQ:CGEN) Estimates - Yahoo Finance
Using portfolio simulators with Compugen Ltd. includedBuy Point Strategy with Profit Protection - Newser
How Compugen Ltd. stock performs during market volatilityPredictive Short-Term Market Reversal Alerts - Newser
Compugen (NASDAQ:CGEN) Downgraded by Wall Street Zen to Sell - Defense World
Using Bollinger Bands to evaluate Compugen Ltd.Free Capital Protection Trading Strategies - Newser
Using data tools to time your Compugen Ltd. exitForecast Model for Intraday Buy Signals - Newser
Understanding Compugen Ltd.’s price movementFree Weekly Hot Picks With Buy Confidence - Newser
How Efficient Is Compugen Ltd. at Controlling Operating CostsMarket Timing Strategy with Technical Filters - Newser
Compugen Reports Q2 2025 Earnings with Strategic Progress Amid Financial Challenges - AInvest
Compugen Reports Q2 Earnings: Revenue Down, Net Loss Up, and Ovarian Cancer Competition Rises Amid Strong Partnerships and Cash Reserves - AInvest
Compugen (CGEN) Gets a Buy from Leerink Partners - The Globe and Mail
Compugen Ltd. (NASDAQ:CGEN) Q2 2025 Earnings Call Transcript - Insider Monkey
Compugen's COM701 Shifts Focus to Targeting PSOC Patients, With Multiple Catalysts Ahead - AInvest
Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients - Seeking Alpha
Will Compugen Ltd. Stock Benefit from AI and Green Energy TrendsRSI and MACD Signal Summary with Trends - Newser
Compugen Ltd. stock momentum explainedFree ROI Boosting Trade Opportunity Calendar - Newser
Compugen’s COM701 Trial: A Potential Game-Changer in Ovarian Cancer Treatment? - TipRanks
Compugen price target raised to $13 from $10 at Leerink - TipRanks
Compugen Reports Q2 2025 Results and Advances in Immuno-Oncology Trials - The Globe and Mail
Compugen stock price target raised to $13 from $10 at Leerink Partners - Investing.com Australia
Is Compugen Ltd. stock entering bullish territoryReliable Setup Screener with Low Risk - Newser
Compugen Reports Q2 2025 Results and Strategic Progress - TipRanks
Advanced analytics toolkit walkthrough for Compugen Ltd.Trading Watchlist with Real Time Filters - Newser
Compugen Ltd. recovery potential after sell offInvestment Position Summary with Timeframe Forecast - Newser
Intrinsic Value of Compugen Ltd. Stock: Is It Undervalued or OvervaluedFree Wealth Building Stock Market Ideas - Newser
Real time scanner hits for Compugen Ltd. explainedPrice Spike Prediction for Active Traders - Newser
Compugen Ltd. shares fall 1.37% intraday after Q2 2025 earnings call. - AInvest
Compugen Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Compugen Reports Q2 Loss, Misses Revenue Estimates - AInvest
Compugen Announces 2025 Annual General Meeting: Election of Directors and Financial Oversight on Agenda - AInvest
Compugen Ltd. Announces 2025 Annual General Meeting Details - TipRanks
Compugen: Q2 Earnings Snapshot - San Antonio Express-News
Technical signs of recovery in Compugen Ltd.Watchlist Generator for Smart Money Signals - Newser
Can Compugen Ltd. recover in the next quarterWatchlist Generator With Real-Time Entry - Newser
Compugen earnings missed by $0.02, revenue fell short of estimates - Investing.com South Africa
Compugen Q2 Earnings Miss Estimates, Revenue Down 80.6% YoY - AInvest
Compugen Q2 Earnings: $94M Cash Runway Powers Multiple Cancer Drug Trials, ESMO Data Coming - Stock Titan
Compugen Ltd. stock retracement – recovery analysisReal Time Alert System for Market Moves - Newser
Evaluating Compugen Ltd. with trendline analysisBuy and Exit Strategy Based on Momentum - Newser
How institutional ownership impacts Compugen Ltd. stockFree Accurate Buy Point for Momentum Stocks - Newser
Why Compugen Ltd. stock attracts strong analyst attentionFree Step-by-Step Trade Signal Implementation - Newser
How to read the order book for Compugen Ltd.Short Term Opportunity Finder with Tools - Newser
Compugen Ltd expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Compugen (CGEN) to Release Earnings on Wednesday - Defense World
Compugen Ltd. Breakout Confirmed by Volume MetricsSmart Investment Tips Gaining Popularity Among Analysts - metal.it
Buy Signal for Compugen Ltd. Stock Key Technical Indicators to WatchFree Weekly Stock Opportunity Radar Scanner - Newser
0.24%
3.39%
자본화:
|
볼륨(24시간):